Selected research
Industry Growth & Trends
Global T Cell Antigen Gp39 Industry Growth and Trends Forecast to 2032
Market perspective
The global T Cell Antigen Gp39 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global T Cell Antigen Gp39 market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The T Cell Antigen Gp39 market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global T Cell Antigen Gp39 market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to T Cell Antigen Gp39.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global T Cell Antigen Gp39 market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
T Cell Antigen Gp39 Market by Company
Biogen, Inc.
XL-protein GmbH
Targovax AS
MedImmune, LLC
Juno Therapeutics Inc.
ImmuNext, Inc.
eTheRNA Immunotherapies NV
Bristol-Myers Squibb Company
T Cell Antigen Gp39 Segment by Type
ECI-006
Hepatitis B Vaccine
ISF-35
INX-021
Others
T Cell Antigen Gp39 Segment by Application
Graft Versus Host Disease
Panceratic Cancer
Breast Cancer
Bladder Cancer
Others
T Cell Antigen Gp39 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of T Cell Antigen Gp39 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ECI-006
- Hepatitis B Vaccine
- ISF-35
- INX-021
- Others
Applications
- Graft Versus Host Disease
- Panceratic Cancer
- Breast Cancer
- Bladder Cancer
- Others
Companies covered
- Biogen, Inc.
- XL-protein GmbH
- Targovax AS
- MedImmune, LLC
- Juno Therapeutics Inc.
- ImmuNext, Inc.
- eTheRNA Immunotherapies NV
- Bristol-Myers Squibb Company
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global T Cell Antigen Gp39 Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global T Cell Antigen Gp39 Sales Estimates and Forecasts (2021-2032)
- 1.3 T Cell Antigen Gp39 Market by Type
- 1.3.1 ECI-006
- 1.3.2 Hepatitis B Vaccine
- 1.3.3 ISF-35
- 1.3.4 INX-021
- 1.3.5 Others
- 1.4 Global T Cell Antigen Gp39 Market Size by Type
- 1.4.1 Global T Cell Antigen Gp39 Market Size Overview by Type (2021-2032)
- 1.4.2 Global T Cell Antigen Gp39 Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global T Cell Antigen Gp39 Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
- 1.5.4 South America T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 T Cell Antigen Gp39 Industry Trends
- 2.2 T Cell Antigen Gp39 Industry Drivers
- 2.3 T Cell Antigen Gp39 Industry Opportunities and Challenges
- 2.4 T Cell Antigen Gp39 Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by T Cell Antigen Gp39 Revenue (2021-2026)
- 3.2 Global Top Players by T Cell Antigen Gp39 Sales (2021-2026)
- 3.3 Global Top Players by T Cell Antigen Gp39 Price (2021-2026)
- 3.4 Global T Cell Antigen Gp39 Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global T Cell Antigen Gp39 Major Company Production Sites & Headquarters
- 3.6 Global T Cell Antigen Gp39 Company, Product Type & Application
- 3.7 Global T Cell Antigen Gp39 Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global T Cell Antigen Gp39 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025
- 3.8.3 2025 T Cell Antigen Gp39 Tier 1, Tier 2, and Tier 3
4 T Cell Antigen Gp39 Regional Status and Outlook
- 4.1 Global T Cell Antigen Gp39 Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global T Cell Antigen Gp39 Historic Market Size by Region
- 4.2.1 Global T Cell Antigen Gp39 Sales in Volume by Region (2021-2026)
- 4.2.2 Global T Cell Antigen Gp39 Sales in Value by Region (2021-2026)
- 4.2.3 Global T Cell Antigen Gp39 Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global T Cell Antigen Gp39 Forecasted Market Size by Region
- 4.3.1 Global T Cell Antigen Gp39 Sales in Volume by Region (2027-2032)
- 4.3.2 Global T Cell Antigen Gp39 Sales in Value by Region (2027-2032)
- 4.3.3 Global T Cell Antigen Gp39 Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 T Cell Antigen Gp39 by Application
- 5.1 T Cell Antigen Gp39 Market by Application
- 5.1.1 Graft Versus Host Disease
- 5.1.2 Panceratic Cancer
- 5.1.3 Breast Cancer
- 5.1.4 Bladder Cancer
- 5.1.5 Others
- 5.2 Global T Cell Antigen Gp39 Market Size by Application
- 5.2.1 Global T Cell Antigen Gp39 Market Size Overview by Application (2021-2032)
- 5.2.2 Global T Cell Antigen Gp39 Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global T Cell Antigen Gp39 Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
- 5.3.4 South America T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Biogen, Inc.
- 6.1.1 Biogen, Inc. Company Information
- 6.1.2 Biogen, Inc. Business Overview
- 6.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
- 6.1.5 Biogen, Inc. Recent Developments
- 6.2 XL-protein GmbH
- 6.2.1 XL-protein GmbH Company Information
- 6.2.2 XL-protein GmbH Business Overview
- 6.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
- 6.2.5 XL-protein GmbH Recent Developments
- 6.3 Targovax AS
- 6.3.1 Targovax AS Company Information
- 6.3.2 Targovax AS Business Overview
- 6.3.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
- 6.3.5 Targovax AS Recent Developments
- 6.4 MedImmune, LLC
- 6.4.1 MedImmune, LLC Company Information
- 6.4.2 MedImmune, LLC Business Overview
- 6.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
- 6.4.5 MedImmune, LLC Recent Developments
- 6.5 Juno Therapeutics Inc.
- 6.5.1 Juno Therapeutics Inc. Company Information
- 6.5.2 Juno Therapeutics Inc. Business Overview
- 6.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
- 6.5.5 Juno Therapeutics Inc. Recent Developments
- 6.6 ImmuNext, Inc.
- 6.6.1 ImmuNext, Inc. Company Information
- 6.6.2 ImmuNext, Inc. Business Overview
- 6.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
- 6.6.5 ImmuNext, Inc. Recent Developments
- 6.7 eTheRNA Immunotherapies NV
- 6.7.1 eTheRNA Immunotherapies NV Company Information
- 6.7.2 eTheRNA Immunotherapies NV Business Overview
- 6.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
- 6.7.5 eTheRNA Immunotherapies NV Recent Developments
- 6.8 Bristol-Myers Squibb Company
- 6.8.1 Bristol-Myers Squibb Company Company Information
- 6.8.2 Bristol-Myers Squibb Company Business Overview
- 6.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
- 6.8.5 Bristol-Myers Squibb Company Recent Developments
7 North America by Country
- 7.1 North America T Cell Antigen Gp39 Sales by Country
- 7.1.1 North America T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America T Cell Antigen Gp39 Sales by Country (2021-2026)
- 7.1.3 North America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
- 7.2 North America T Cell Antigen Gp39 Market Size by Country
- 7.2.1 North America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America T Cell Antigen Gp39 Market Size by Country (2021-2026)
- 7.2.3 North America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe T Cell Antigen Gp39 Sales by Country
- 8.1.1 Europe T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe T Cell Antigen Gp39 Sales by Country (2021-2026)
- 8.1.3 Europe T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
- 8.2 Europe T Cell Antigen Gp39 Market Size by Country
- 8.2.1 Europe T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe T Cell Antigen Gp39 Market Size by Country (2021-2026)
- 8.2.3 Europe T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific T Cell Antigen Gp39 Sales by Country
- 9.1.1 Asia-Pacific T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific T Cell Antigen Gp39 Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific T Cell Antigen Gp39 Market Size by Country
- 9.2.1 Asia-Pacific T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific T Cell Antigen Gp39 Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America T Cell Antigen Gp39 Sales by Country
- 10.1.1 South America T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America T Cell Antigen Gp39 Sales by Country (2021-2026)
- 10.1.3 South America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
- 10.2 South America T Cell Antigen Gp39 Market Size by Country
- 10.2.1 South America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America T Cell Antigen Gp39 Market Size by Country (2021-2026)
- 10.2.3 South America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa T Cell Antigen Gp39 Sales by Country
- 11.1.1 Middle East and Africa T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa T Cell Antigen Gp39 Market Size by Country
- 11.2.1 Middle East and Africa T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa T Cell Antigen Gp39 Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 T Cell Antigen Gp39 Value Chain Analysis
- 12.1.1 T Cell Antigen Gp39 Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 T Cell Antigen Gp39 Production Mode & Process
- 12.2 T Cell Antigen Gp39 Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 T Cell Antigen Gp39 Distributors
- 12.2.3 T Cell Antigen Gp39 Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst